GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Surrozen Inc.
Shares of Surrozen, a biotech company focused on regenerative medicine, reflect the sector's binary risks. The price trajectory depends entirely on the results of clinical trials and regulatory decisions regarding its drugs.
Share prices of companies in the market segment - Stem_cells
Surrozen is a biotech company developing a new class of targeted therapies that restore damaged tissue by modulating the Wnt signaling pathway. We classify it in the "Stem Cells" sector. The graph below shows the dynamics of this regenerative field.
Broad Market Index - GURU.Markets
Surrozen is a biotech company developing tissue regeneration drugs by modulating the Wnt signaling pathway. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Surrozen shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
SRZN - Daily change in the company's share price Surrozen Inc.
For Surrozen, Inc., a regenerative medicine company, daily price volatility is a measure of sensitivity to scientific breakthroughs in stem cells. This metric is an important element in evaluating innovative companies in the life sciences sector.
Daily change in the price of a set of shares in a market segment - Stem_cells
Surrozen, Inc. is a biotech company. This chart highlights the sector's extreme volatility. Comparison with SRZN, which focuses on regenerative medicine, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Surrozen is a biotech company working in the field of regenerative medicine using stem cell biology. Its shares are a bet on breakthrough technologies of the future. Their high volatility, based on scientific data, contributes to the dynamics of the entire innovation sector.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Surrozen Inc.
Surrozen, Inc.'s year-over-year performance is a story of developing a new class of regenerative therapies. Its 12-month market cap is entirely dependent on early clinical trial data for its drugs targeting the Wnt signaling pathway. Success in this complex area could lead to a breakthrough in the treatment of liver and intestinal diseases.
Annual dynamics of market capitalization of the market segment - Stem_cells
Surrozen, Inc. is an early-stage biotech company developing a new class of tissue regeneration drugs. Its stock performance is entirely dependent on the results of preclinical and clinical trials. The chart reflects the enormous potential of its scientific platform and the significant risks involved.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Surrozen is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Surrozen Inc.
Surrozen is a biotech company working in the field of regenerative medicine. Its monthly valuation depends almost entirely on progress in its preclinical and early clinical trials. News of its platform validation or partnerships are the main catalysts for its stock.
Monthly dynamics of market capitalization of the market segment - Stem_cells
Surrozen is a biotech company developing drugs that mimic natural tissue regeneration processes by targeting the Wnt signaling pathway. This could help treat liver and intestinal diseases. The graph below shows the dynamics of the biotech sector, where regenerative medicine is one of the most advanced areas.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Surrozen is a biotech company developing tissue regeneration drugs. Its shares represent a venture bet on the success of a breakthrough scientific platform. Their performance is entirely dependent on the results of preclinical and clinical trials and has no connection to general market trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Surrozen Inc.
Surrozen, Inc., a biotech company developing tissue regeneration drugs, is experiencing high volatility. Weekly stock performance is driven by news about preclinical and clinical trials, reflecting the high risks and enormous potential of regenerative medicine.
Weekly dynamics of market capitalization of the market segment - Stem_cells
Surrozen is involved in regenerative medicine, which aims to repair tissue. This is a cutting-edge but risky sector. The chart will help investors determine whether Surrozen's weekly stock fluctuations are a unique response to research progress or simply reflect the overall volatility in the stem cell sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Surrozen is a biotech company working in the field of regenerative medicine. Its shares exist in a world of their own, where research data is king. The chart shows that Surrozen's performance is almost uncorrelated with the market, moving based on its own unique news.
Market capitalization of the company, segment and market as a whole
SRZN - Market capitalization of the company Surrozen Inc.
Surrozen's market capitalization is a financial map of regenerative medicine. This biotech company's stock price reflects the hopes for its platform, which aims to repair damaged tissue by activating Wnt signaling pathways. Its volatility reflects the risks and enormous potential for treating liver diseases and other organs.
SRZN - Share of the company's market capitalization Surrozen Inc. within the market segment - Stem_cells
Surrozen's market share in the regenerative medicine sector reflects its cutting-edge research in tissue repair. Its market share is based almost entirely on the potential of its scientific platform, which targets the treatment of serious diseases. It is a bet on a future revolution in medicine.
Market capitalization of the market segment - Stem_cells
Surrozen is seeking to create a breakthrough in regenerative medicine by developing antibody-based drugs. The chart below shows the overall market capitalization of the entire biotech sector. Its dynamics reflect investors' high hopes that science will be able to restore damaged tissue.
Market capitalization of all companies included in a broad market index - GURU.Markets
Surrozen is a biotech company developing drugs that stimulate tissue regeneration using the Wnt signaling pathway. Its market cap is a bet on breakthroughs in regenerative medicine. The chart below shows the economic weight of companies at the forefront of science.
Book value capitalization of the company, segment and market as a whole
SRZN - Book value capitalization of the company Surrozen Inc.
For Surrozen, a biotech company, book value is its capital and laboratory equipment. The chart below shows the financial and scientific resources devoted to regenerative medicine. Its dynamics are a history of capital management during long and risky research.
SRZN - Share of the company's book capitalization Surrozen Inc. within the market segment - Stem_cells
Surrozen is a biotech company developing drugs aimed at tissue regeneration. Its main asset is its scientific platform. The share of tangible assets will be low, reflecting its focus on R&D, where the primary focus is on laboratories rather than large-scale manufacturing facilities.
Market segment balance sheet capitalization - Stem_cells
Surrozen is a research-stage biotech company. Its value lies in its scientific platform, not its manufacturing facilities. This is a classic "light" model. Is this focus on R&D the norm for its sector? The chart below shows the combined physical "weight" of the entire biopharmaceutical industry.
Book value of all companies included in the broad market index - GURU.Markets
Surrozen's balance sheet represents capital invested in a scientific platform for tissue regeneration by modulating the Wnt signaling pathway. The company's assets represent financial resources focused on one of the most promising areas in regenerative medicine. The chart shows the scale of these future investments.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Surrozen Inc.
Surrozen is a biotech company developing tissue regeneration technology by modulating the Wnt signaling pathway. It has no tangible assets other than cash. Its market capitalization is a bet on its platform's potential to treat severe liver and intestinal diseases. The chart reflects investors' faith in the breakthrough potential of regenerative medicine.
Market to book capitalization ratio in a market segment - Stem_cells
Surrozen is a biotech company working in the field of regenerative medicine. Its value lies in its unique scientific platform, not its tangible assets. This metric clearly demonstrates how market capitalization, based on the promise of future breakthrough drugs, exceeds the value of its equipment.
Market to book capitalization ratio for the market as a whole
Surrozen is a biotech company focused on developing drugs that stimulate tissue regeneration. The chart shows how the market values this innovative approach to medicine. The company's market capitalization reflects investors' bet that its scientific platform can "repair" damaged organs, a huge but very risky prospect.
Debts of the company, segment and market as a whole
SRZN - Company debts Surrozen Inc.
Surrozen is a biotech company focused on developing drugs that restore tissue by modulating Wnt signaling pathways. Debt during preclinical and early clinical trials is a way to finance breakthrough but risky research, as this chart illustrates.
Market segment debts - Stem_cells
Surrozen is a biotech company developing tissue regeneration drugs based on its understanding of the biology of the Wnt signaling pathway. This is fundamental science, requiring significant investment. The chart illustrates the financial norms for the biotech sector, against which Surrozen is raising capital to transform scientific discoveries into potential treatments.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Surrozen Inc.
Surrozen is working in the cutting-edge field of regenerative medicine, developing stem cell-based treatments. This field requires massive, long-term investments in research. This chart clearly demonstrates the proportion of debt in funding this risky research, allowing us to assess the company's financial vulnerability on its path to success.
Market segment debt to market segment book capitalization - Stem_cells
Developing stem cell-based therapies for tissue regeneration, like Surrozen's, is one of the most complex and capital-intensive areas of biotechnology. This chart shows how the sector as a whole funds its cutting-edge research. It allows us to assess how dependent Surrozen's financial model is on external capital to advance its innovative platform.
Debt to book value of all companies in the market
Surrozen researches tissue regeneration using stem cells—the cutting edge of biotechnology. Financing for such pioneering research often involves debt. The chart shows how this innovative company's debt load compares to more traditional and established sectors of the economy.
P/E of the company, segment and market as a whole
P/E - Surrozen Inc.
This metric for Surrozen, Inc., a biotech company working in the field of regenerative medicine, reflects expectations. Its value is determined not by current profits, but by investors' faith in its innovative tissue repair platform. The chart shows how highly the market values the company's scientific potential.
P/E of the market segment - Stem_cells
This indicator represents the average valuation for biotech companies working in regenerative medicine, like Surrozen. It reflects the overall level of hope and expectation in this cutting-edge field of science. The chart serves as a barometer of investor confidence in the future of tissue repair technologies.
P/E of the market as a whole
Surrozen is a biotech company working on tissue regeneration using a unique technology targeting the Wnt signaling pathway. Its valuation is based on the potential of this platform to treat various diseases. This chart reflects investor interest in breakthrough technologies. It helps us understand whether Surrozen is valued based on its scientific approach or as part of the broader biotech sector.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Surrozen Inc.
Surrozen is a biotech company developing drugs targeting the Wnt signaling pathway for tissue regeneration in severe diseases, such as liver disease. The company's future depends on the success of its innovative approach in clinical trials. This chart reflects investor speculative expectations regarding a breakthrough in regenerative medicine and the potential of its platform.
%20P%2FE%20Surrozen%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Surrozen-Inc.&v=1772653293648 "Chart of the company's future (projected) P/E Surrozen Inc.")
Future (projected) P/E of the market segment - Stem_cells
Surrozen is a biotech company developing drugs that target the Wnt signaling pathway, which plays a key role in tissue regeneration. This is a promising area in regenerative medicine. The chart reflects expectations for the biotech sector, providing an opportunity to assess how highly the market values Surrozen's scientific platform and development potential.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Stem_cells&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Stem_cells&v=1772653293652 "Future (projected) P/E graph of the market segment - Stem_cells")
Future (projected) P/E of the market as a whole
Surrozen is a biotech company working on tissue regeneration using antibodies targeting the Wnt signaling pathway. This is a cutting-edge, yet very early, field of science. This graph of overall expectations shows how willing investors are to invest in fundamental research. Market optimism is critical to attracting the capital needed to test such bold scientific hypotheses.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772653293672 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Surrozen Inc.
Surrozen is a biotech company focused on developing drugs that modulate the Wnt signaling pathway for tissue regeneration. This chart shows the financial health of the company at the forefront of regenerative medicine. Profit is a distant goal, and current performance reflects the high costs of preclinical and early clinical trials.
Profit of companies in the market segment - Stem_cells
Sunlands Technology Group is a Chinese company that provides online courses for adult professional development. Its profitability depends on demand for continuing education and the regulatory environment. This chart reflects the state of a sector that benefits from people's desire for career advancement but is heavily dependent on government policies regarding education and online services.
Overall market profit
Surrozen is a biotech company focused on regenerative medicine and the development of drugs that stimulate tissue repair. Its value is determined by its scientific potential and early research results. It is an example of a business operating in a scientific world where successes and failures do not directly correlate with overall corporate profitability.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Surrozen Inc.
Surrozen is a biotech company developing drugs for tissue regeneration by targeting the Wnt signaling pathway. Its revenue outlook is long-term and depends on the success of clinical trials. This chart reflects analyst expectations regarding the potential of regenerative medicine and Surrozen's ability to develop treatments for liver and intestinal diseases.
%20profit%20of%20the%20company%20Surrozen%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Surrozen-Inc.&v=1772653293778 "Graph of future (projected) profit of the company Surrozen Inc.")
Future (predicted) profit of companies in the market segment - Stem_cells
Surrozen is a biotech company that harnesses the body's regenerative potential to repair damaged tissue. Its platform targets the activation of the Wnt signaling pathway. This chart shows profitability forecasts for the biotech sector. It reflects investors' belief in the breakthrough potential of regenerative medicine and its commercial prospects.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Stem_cells&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Stem_cells&v=1772653293784 "Graph of future (predicted) profits of companies in a market segment - Stem_cells")
Future (predicted) profit of the market as a whole
Surrozen develops stem cell-based drugs for tissue regeneration. The company's success is determined by scientific breakthroughs, not economic cycles. However, the overall corporate profit projections presented here affect investors' risk appetite and, consequently, Surrozen's ability to attract funding for its time-consuming and expensive research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772653293810 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Surrozen Inc.
Surrozen is a biotech company developing drugs that modulate the Wnt signaling pathway for tissue regeneration. The company is in the preclinical stage and has no revenue from its products. The chart reflects the speculative valuation of its revolutionary platform, which has the potential to treat a wide range of diseases associated with tissue damage.
P/S market segment - Stem_cells
Surrozen, Inc. is a clinical-stage biotech company developing tissue regeneration therapies by modulating the Wnt signaling pathway. Its pipeline targets severe liver and intestinal diseases. This chart shows the average market valuation for the sector, allowing one to assess how the market perceives the potential of Surrozen's breakthrough technologies.
P/S of the market as a whole
Surrozen is a biotech company developing drugs that stimulate tissue regeneration via the Wnt signaling pathway. This is a cutting-edge field of biology. This chart, showing average market valuations, clearly demonstrates the gap between the valuations of companies with current sales and the value of scientific platforms with long-term potential.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Surrozen Inc.
Surrozen is a biotech company focused on developing drugs that restore tissue by modulating the Wnt signaling pathway. This chart reflects investors' confidence in the future breakthroughs of its platform. The valuation is based on potential future revenue from tissue regeneration drugs, such as those used to treat liver disease.
%20P%2FS%20Surrozen%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Surrozen-Inc.&v=1772653293934 "The graph of the company's future (projected) P/S Surrozen Inc.")
Future (projected) P/S of the market segment - Stem_cells
Surrozen is a biotech company developing tissue regeneration drugs by targeting the Wnt signaling pathway. Its technologies may have applications in the treatment of liver and intestinal diseases. The chart shows the premium investors are willing to pay for Surrozen's future sales, reflecting the high potential of its breakthrough scientific platform.
%20P%2FS%20market%20segment%20graph%20-%20Stem_cells&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Stem_cells&v=1772653293974 "Future (projected) P/S market segment graph - Stem_cells")
Future (projected) P/S of the market as a whole
This chart reflects the hopes associated with regenerative medicine. Surrozen, developing drugs that stimulate tissue repair, is at the forefront of this exciting field of science. The potential of their technology to treat a wide range of conditions, from liver disease to inflammation, supports long-term optimism among investors in the biotech sector.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772653294008 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Surrozen Inc.
Surrozen is a clinical-stage biotech company focused on regenerative medicine through targeting the Wnt signaling pathway. The company currently has no commercial products, and its revenue curve reflects revenue from potential partnerships, not sales. Future growth will depend on the success of clinical trials.
Sales of companies in the market segment - Stem_cells
Surrozen is a biotech company developing a new class of drugs that selectively activate tissue regeneration pathways in the body to treat severe liver and intestinal diseases. This chart shows total revenue in the stem cell niche. It demonstrates the potential of regenerative medicine, where Surrozen strives to create breakthrough treatments.
Overall market sales
Surrozen is a biotech company developing tissue-specific antibodies to repair damaged tissues and organs using Wnt signaling pathways. Currently in the research stage, its future depends on success in clinical trials. This overall economic climate is impacting investor willingness to invest in breakthrough, yet risky, regenerative technologies.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Surrozen Inc.
Surrozen is a biotech company developing drugs that mimic natural tissue regeneration processes, with a focus on liver diseases. Its future depends on the success of clinical trials. The chart shows analysts' speculative revenue forecasts, betting on a breakthrough in regenerative medicine.
%20sales%20of%20the%20company%20Surrozen%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Surrozen-Inc.&v=1772653294128 "Schedule of future (projected) sales of the company Surrozen Inc.")
Future (projected) sales of companies in the market segment - Stem_cells
Surrozen is a biotech company developing tissue regeneration drugs based on stimulation of the Wnt signaling pathway. The company's success depends on the results of clinical trials for liver and intestinal diseases. This chart displays projected sales for the entire regenerative medicine segment, highlighting expectations for the development of this innovative field.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Stem_cells&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Stem_cells&v=1772653294166 "Schedule of future (projected) sales of companies in the market segment - Stem_cells")
Future (projected) sales of the market as a whole
Surrozen is a biotech company developing tissue regeneration drugs by modulating Wnt signaling pathways. Its future depends on the success of preclinical and clinical trials. This overall economic activity profile influences the overall investment climate and investor willingness to invest in breakthrough, yet early-stage, scientific platforms.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772653294192 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Surrozen Inc.
Surrozen is a biotech company working in the cutting-edge field of regenerative medicine. This metric reflects the financial side of its scientific ambitions. It demonstrates the level of investment in research and development required to commercialize its innovative platform and achieve future profitability.
Market segment marginality - Stem_cells
Surrozen is a biotech company developing tissue regeneration therapies based on its unique platform. For such companies, profitability is a long-term goal, dependent on the success of clinical trials. This metric reflects its operational structure and the intensity of its investment in cutting-edge stem cell science.
Market marginality as a whole
Surrozen is an early-stage biotech company developing tissue regeneration therapies by targeting the Wnt signaling pathway. Their potential is enormous, but depends on successful research. This overall profitability curve is irrelevant to them; their fate lies in the hands of the scientists and investors who believe in their breakthrough stem cell technology.
Employees in the company, segment and market as a whole
Number of employees in the company Surrozen Inc.
Surrozen is a biotech company working on antibody-based tissue regeneration. While in the research stage, its main asset is intellectual capital. This graph shows the size of its research team. Growth here indicates progress in preclinical research and approaching clinical trials.
Share of the company's employees Surrozen Inc. within the market segment - Stem_cells
Surrozen aims to open a new avenue in regenerative medicine by targeting the Wnt signaling pathway. This graph shows the concentration of leading scientists in the field of stem cell biology. This proportion reflects its role as a pioneer in the development of methods for tissue repair.
Number of employees in the market segment - Stem_cells
Surrozen, Inc. is a biotechnology company developing drugs that selectively activate the Wnt tissue regeneration pathway. This chart shows the company's overall activity in the field of regenerative medicine and stem cells. It illustrates the cutting edge of science, where Surrozen is working to create breakthrough treatments for the restoration of damaged organs and tissues.
Number of employees in the market as a whole
Surrozen is focused on developing drugs that target tissue regeneration via the Wnt signaling pathway. This is one of the most advanced areas in regenerative medicine. This chart of total employment also reflects the contribution of these R&D companies, where every research associate represents a step toward creating technologies capable of restoring damaged human organs and tissues.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Surrozen Inc. (SRZN)
Surrozen, Inc. is a biotech company developing tissue regeneration drugs. The extremely high market capitalization per employee, visible in this chart, is a classic example of biotech. The market is investing in the potential of the unique technology and patents developed by a small team of scientists, rather than in day-to-day operations.
%20of%20the%20company%20Surrozen%20Inc.%20(SRZN)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Surrozen-Inc.-SRZN&v=1772653294381 "Chart of market capitalization per employee (in thousands of dollars) of the company Surrozen Inc. (SRZN)")
Market capitalization per employee (in thousands of dollars) in the market segment - Stem_cells
Surrozen is a biotech company working in the field of regenerative medicine using stem cells. Their market cap is based on the potential of their scientific platform. This chart shows the enormous future value the market places on the work of each of the company's scientists. The high value here reflects investors' bet on a breakthrough in one of the most cutting-edge fields of medicine.
%20by%20market%20segment%20-%20Stem_cells&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Stem_cells&v=1772653294391 "Market capitalization per employee (in thousands of dollars) by market segment - Stem_cells")
Market capitalization per employee (in thousands of dollars) for the overall market
Surrozen, Inc. is a biotech company working on antibody-based tissue regeneration. Its valuation is based on the potential of its scientific platform. Like many preclinical companies, its high market capitalization per employee reflects investors' belief that a small team of scientists can create a breakthrough technology.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772653294423 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Surrozen Inc. (SRZN)
Surrozen is a clinical-stage biotech company working in the field of regenerative medicine. They are trying to develop drugs that repair tissue. This is cutting-edge science, but it's expensive. This chart shows the "cost" of this research: it measures the burn rate per highly qualified scientist.
%20Chart%20Surrozen%20Inc.%20(SRZN)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Surrozen-Inc.-SRZN&v=1772653294433 "Company Profit Per Employee (in thousands of dollars) Chart Surrozen Inc. (SRZN)")
Profit per employee (in thousands of dollars) in the market segment - Stem_cells
Surrozen is a biotech company working in the field of regenerative medicine. During the R&D phase, this ROE is negative. This chart serves as a benchmark for the future. The company's entire value lies in its scientific team and the potential of its tissue repair platform. Clinical success could lead to results that significantly exceed the benchmark.
%20in%20the%20market%20segment%20-%20Stem_cells&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Stem_cells&v=1772653294459 "Chart of profit per employee (in thousands of dollars) in the market segment - Stem_cells")
Profit per employee (in thousands of dollars) for the market as a whole
Surrozen (SRZN) is a biotech company working on regenerative medicine, attempting to "repair" tissue using specific antibodies. Their business is focused on cutting-edge science, far removed from commercialization. This chart shows that each research employee represents a significant R&D expense, and the return on investment is negative.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772653294498 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Surrozen Inc. (SRZN)
For Surrozen, a biotech company working on tissue regeneration, this graph reflects early-stage research. Revenue per employee likely comes from grants or partnerships, and significant growth is only possible after successful clinical trials and commercialization of its platform.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Surrozen-Inc.-SRZN&v=1772653294519 "Sales chart per company employee Surrozen Inc. (SRZN)")
Sales per employee in the market segment - Stem_cells
Surrozen is a biotech company working on drugs that modulate the Wnt signaling pathway, with a focus on tissue regeneration. This is an early-stage R&D company. This metric reflects the average revenue per employee in the segment. It allows one to assess how productive their R&D team is compared to other biotechs working in the field of regenerative medicine.
Sales per employee for the market as a whole
Surrozen (SRZN) is a clinical-stage biopharmaceutical company developing tissue regeneration therapies. Currently, its staff consists entirely of researchers. This metric is critical for SRZN: it's at zero. Future growth will depend on successful licensing of their platform or a partnership with a major pharmaceutical company.
Short shares by company, segment and market as a whole
Shares shorted by company Surrozen Inc. (SRZN)
Surrozen is a biotech company attempting to treat diseases by modulating the Wnt signaling pathway. This is a highly complex and historically challenging target for drug development. This chart shows how many investors are betting that the company will be unable to safely and effectively "hack" this pathway, and that its clinical programs will fail.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Surrozen-Inc.-SRZN&v=1772653294548 "Short Shares Chart for the Company Surrozen Inc. (SRZN)")
Shares shorted by market segment - Stem_cells
Surrozen (SRZN) is an early-stage biopharmaceutical company focused on regenerative medicine by targeting the Wnt pathway for tissue repair. This chart shows the aggregate bearish bets on the regenerative medicine sector. It reflects investors' extreme skepticism regarding the very long and risky path from the lab to a real-world treatment.
Shares shorted by the overall market
Surrozen (SRZN) is a clinical-stage biotech. Its value is based on future expectations. When this market fear indicator rises, investors' risk appetite evaporates. They are the first to sell speculative, loss-making biotechs like SRZN in favor of safer assets.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Surrozen Inc. (SRZN)
Surrozen is a biotech company working in the complex field of tissue regeneration. This is a high-risk bet on their R&D platform. This chart measures the extremes of speculative sentiment. It shows when the stock is "overheated" (overbought) on positive lab news or "oversold" due to long-term R&D.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Surrozen-Inc.-SRZN&v=1772653294588 "RSI 14 indicator chart for the company's stock Surrozen Inc. (SRZN)")
RSI 14 Market Segment - Stem_cells
Surrozen (SRZN) is a "regenerative" medicine company. They develop "smart" antibodies that stimulate the Wnt pathway to repair tissue (liver, intestines). The "Stem_cells" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It's vital to understand: is SRZN's growth due to their R&D, or is the entire biotech sector "overheated"?
RSI 14 for the overall market
Surrozen (SRZN) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast SRZN (Surrozen Inc.)
Surrozen is a biotech company developing drugs that repair and regenerate tissue by modulating the Wnt signaling pathway. This chart shows the average target price. Analysts' estimates are based on preclinical data and the potential of this platform for treating liver and intestinal diseases.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-SRZN-Surrozen-Inc.&v=1772653294649 "A chart showing analyst consensus forecasts for the expected stock price. SRZN (Surrozen Inc.)")
The difference between the consensus estimate and the actual stock price SRZN (Surrozen Inc.)
Surrozen is a biotech company attempting to "hack" the Wnt signaling pathway. Their goal is to create drugs that can regenerate (repair) damaged tissue. This chart shows the difference between the market valuation and the consensus forecast. It reveals whether experts believe in this complex but potentially revolutionary science.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-SRZN-Surrozen-Inc.&v=1772653294674 "A chart showing the difference between the consensus forecast and the actual stock price. SRZN (Surrozen Inc.)")
Analyst consensus forecast for stock prices by market segment - Stem_cells
Surrozen is a biotech company developing drugs that "fix" the Wnt signaling pathway to regenerate tissue in liver and intestinal diseases. This chart reflects general expectations for the stem cell (and regeneration) sector, demonstrating whether experts believe this R&D platform will be successful.
Analysts' consensus forecast for the overall market share price
Surrozen (SRZN) is a biopharmaceutical company working in the field of regenerative medicine. They develop drugs that aim to "turn on" the body's ability to repair tissue. This chart shows the overall risk appetite, reflecting the market's willingness to fund breakthrough but high-risk scientific R&D platforms.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Surrozen Inc.
Surrozen is a clinical-stage biotech company working in regenerative medicine. Their R&D platform targets the Wnt signaling pathway, which is the master switch for tissue repair and regeneration (for example, in the liver or intestine). This graph is a clear indicator of their faith in their deep science, reflecting their (very risky) R&D progress.
AKIMA Market Segment Index - Stem_cells
Surrozen is a biotech company working on a therapy that modulates the Wnt pathway, which is crucial for tissue regeneration (e.g., liver regeneration). This chart shows the average index for the biotech sector. It provides investors with a benchmark for how Surrozen, which is working on a breakthrough technology, compares to the average.
The AKIM Index for the overall market
Surrozen is a biotech company developing antibodies for tissue regeneration by modulating the Wnt signaling pathway (gut, liver, eye). This chart, reflecting the market average, provides a macro backdrop. It helps assess how this early scientific story compares to the overall economic trends impacting regenerative medicine.
